^
    Back
    Association details:
    Biomarker:HRAS overexpression
    Cancer:Neuroendocrine Tumor
    Drug:Lenvima (lenvatinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2022
    Title:

    HRAS expression predicts Lenvatinib responsiveness in human primary gastroenteropancreatic neuroendocrine tumor cells.

    Published date:
    05/26/2022
    Excerpt:
    A high expression of HRAS in the tumor tissues compared to the matched healthy tissues significantly correlated with responsiveness of primary cells to Lenvatinib. All 5 non-responder patients showed low expression of HRAS, while of the 6 responder patients, 5 showed a high HRAS expression and only 1 low.
    DOI:
    10.1200/JCO.2022.40.16_suppl.e16211
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Front Endocrinol (Lausanne)
    Title:

    HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors

    Published date:
    01/20/2023
    Excerpt:
    We observed that the overexpression of HRAS in the original tumor tissue compared to the matched healthy tissue significantly correlated with responsiveness of primary cells to lenvatinib (p=.048)….Lenvatinib appears to be a highly effective drug for the treatment of NETs. The evaluation of HRAS expression in the tumor tissue might improve patient selection and optimize therapeutic outcome.
    DOI:
    10.3389/fendo.2022.1045038